3 results about "Diabetes Therapy" patented technology

The application discloses an intelligent self-adaptive ablation system, an ablation catheter and a method for type 2 diabetes treatment, and belongs to the technical field of medical devices. The system comprises an intelligent control host and an electrode unit library. The intelligent control host integrates a main control processor, a motion prediction decision unit, an intelligent driving control module and an intelligent energy control module. The electrode unit library comprises a plurality of electrode units with different structures. The main control processor and the motion prediction decision unit automatically select an optimal electrode unit based on the duodenal cavity tract anatomical form obtained by a sensing component. The intelligent driving control module receives instructions to drive the selected electrode unit to adapt to the cavity environment. The intelligent energy control module provides controlled ablation energy to the electrode unit. Through the "sensing-decision-execution" closed loop, the application realizes self-adaptive and precise ablation treatment in the duodenal dynamic environment, thereby solving the problems of passive control strategy and lack of prospective compensation in the prior art which depend on a single electrode form.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention relates to the technical field of biological medicine and gene therapy, in particular to a nucleic acid delivery system for targeting pancreatic beta cells and application of the nucleic acid delivery system. The composition comprises a nano-composite formed by a cationic polymer modified by a targeting ligand and siRNA (small interfering Ribonucleic Acid), the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is the siRNA of the target DYRK1A (DYRK1A). The invention provides a brand-new pancreatic beta cell targeted delivery platform for gene therapy of type 2 diabetes mellitus. The platform realizes beta cell function regeneration by accurately regulating and controlling DYRK1A gene expression, has targeting property, safety and high efficiency, and provides a new strategy with wide clinical application prospect for diabetes treatment.